Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JDQ443 vs Docetaxel in Advanced KRAS G12C Mutant NSCLC
NCT05132075Phase 3Active, not recruiting
- Sponsor
- Novartis
- Start
- Jun 2022
- Primary completion
- Sep 2026
- Countries
- 25
01
Overview
Phase 3, randomised, open-label trial of opnurasib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Novartis. Primary endpoint: Progression free survival at 24 months. Started Jun 2022; status: active, not recruiting.
02
Drugs
opnurasib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05132075.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05132075.